NCT05410496Active, not recruitingPhase 4
Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection
A Prospective Cohort Study of Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic Hepatitis B Virus Infection
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients with chronic hepatitis B (CHB), therefore TAF may be a good option in kidney or liver transplant patients with chronic HBV infection. The aim of this prospective cohort study is to assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 52 (actual)
- First submitted
- 13 May 2022
- Start date
- 22 Jun 2021
- Primary completion date
- 30 May 2024
- Lead sponsor
- Taichung Veterans General Hospital
- Diseases
- Hepatitis B
- NCT number
- NCT05410496
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 52
- From 22 Jun 2021 to the primary completion date, 30 May 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Co-infected with human immunodeficiency virus (HIV) or hepatitis C virus (HCV)
- Any active malignancies
- Known allergy to tenofovir-contained regimens
Lab values
- End stage renal disease (eGFR \< 15 mL/min/1.73m2)
Other
- Pregnant or breast-feeding women
Who the study is looking for
- At least 20 years of age
- Chronic HBV infection under NA therapy other than TAF
- Underwent kidney and/ or liver transplantation
- Without clinical or pathologic evidence of moderate or severe rejection
- Patients who are indicated for TAF switching therapy, such as concerns in virological response, biochemical response, drug compliance, or safety issues to other NAs.
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Taichung Veterans General Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Unknown status |
| China Medical University Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.